| Main Title |
Impact of pharmacokinetics on the risk assessment of dichloromethane |
| Author |
Blancato, Jerry N. ;
Rhomberg, L.
|
| Other Authors |
|
| CORP Author |
Environmental Protection Agency, Washington, DC. Office of Health and Environmental Assessment. |
| Publisher |
U.S. Environmental Protection Agency, Office of Research and Development, Office of Health and Environmental Assessment, |
| Year Published |
1988 |
| Report Number |
EPA/600/D-88/219 |
| Stock Number |
PB89-173249 |
| Subjects |
Dichloromethane--Toxicology ;
Carcinogenicity testing
|
| Additional Subjects |
Physiology ;
Chloromethanes ;
Bioassay ;
Environmental surveys ;
Exposure ;
Laboratory animals ;
Humans ;
In vitro analysis ;
Metabolism ;
Pharmacokinetics ;
Risk assessment ;
Methane/dichloro ;
Dose response relationships
|
| Holdings |
| Library |
Call Number |
Additional Info |
Location |
Last
Modified |
Checkout
Status |
| NTIS |
PB89-173249 |
Some EPA libraries have a fiche copy filed under the call number shown. |
|
07/26/2022 |
|
| Collation |
8 p. : ill. ; 28 cm. |
| Abstract |
The paper recapitulates the means by which a physiologically based risk assessment for dichloromethane (DCM, methylene chloride) evolved. Two somewhat different physiologically based pharmacokinetic (PBPK) models had been published by Angelo et al. in 1984 and Andersen et al. in 1987. The paper discusses the rationale for the selection and implementation of a PBPK model for purposes of estimating the delivered or effective dose. Also discussed is the rationale used for selecting the scaling method for estimating the equivalency of delivered dose between test species and humans. |
| Notes |
"EPA/600/D-88-219." "May 1988." "PB89-173249." |
